NCT06742515View on ClinicalTrials.gov

Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

August 31, 2028

Conditions
Precursor B-Cell Acute Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab plus Reduced-dose Chemotherapy

Cycle 1: Reduced VCP on day1, IV and Blinatumomab for 2 weeks, IV. Cycle 2: Blinatumomab for 2 weeks, IV and Venetoclax for 2 weeks, oral.

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, Hangzhou

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER